CN118047766A - 一种花菁类近红外荧光标记试剂及其制备方法和应用 - Google Patents
一种花菁类近红外荧光标记试剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN118047766A CN118047766A CN202410168756.0A CN202410168756A CN118047766A CN 118047766 A CN118047766 A CN 118047766A CN 202410168756 A CN202410168756 A CN 202410168756A CN 118047766 A CN118047766 A CN 118047766A
- Authority
- CN
- China
- Prior art keywords
- reaction
- labeling reagent
- tag
- fluorescence labeling
- near infrared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 43
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 41
- 238000001215 fluorescent labelling Methods 0.000 title claims abstract description 33
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- -1 Tag-776-NHS Chemical class 0.000 claims abstract description 11
- 238000003384 imaging method Methods 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 14
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004440 column chromatography Methods 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 239000012044 organic layer Substances 0.000 claims description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 238000002372 labelling Methods 0.000 abstract description 15
- 229960001972 panitumumab Drugs 0.000 abstract description 8
- LOPCOKFMJOYXHI-UHFFFAOYSA-N Cy7 dye Chemical class C1=C(S([O-])(=O)=O)C=C2CC(C=CC=CC=CC=C3N(C4=CC=C(C=C4C3)S(O)(=O)=O)CC)=[N+](CCCCCC(O)=O)C2=C1 LOPCOKFMJOYXHI-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract description 4
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 abstract description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000975 dye Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- KPRGOTLNGIBVFL-GINZOMEDSA-N 7-ketodehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C(=O)C=C21 KPRGOTLNGIBVFL-GINZOMEDSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000006862 quantum yield reaction Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GDIYMWAMJKRXRE-UHFFFAOYSA-N (2z)-2-[(2e)-2-[2-chloro-3-[(z)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole Chemical compound CC1(C)C2=CC=CC=C2N(C)C1=CC=C1C(Cl)=C(C=CC=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC1 GDIYMWAMJKRXRE-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明属于荧光探针领域,具体涉及一种花菁类近红外荧光标记试剂及其制备方法和应用。本发明基于“菁酮法”构建了一个NHS酯功能化的中位2,6‑二甲氧基苯基取代的Cy7染料,即Tag‑776‑NHS,用于标记目标蛋白/抗体。该荧光标记试剂不仅合成简单,重要的是解决了基于经典Cy7染料构建的蛋白标记试剂水溶性和光/化学稳定性差、易于聚集的缺点。本发明用Tag‑776‑NHS荧光标记可特异性靶向EGFR的mAb—帕尼单抗,用来影像A549荷瘤鼠的肿瘤,结果显示,肿瘤与正常组织的荧光信号比率(T/N)高达3.2,高于临床可接受的阈值2.0。
Description
技术领域
本发明属于荧光探针技术领域,具体涉及一种花菁类近红外荧光标记试剂及其制备方法和应用。
背景技术
由于具有无放射性、可视化、操作简单和高灵敏度等优点,荧光标记技术已成为现代生物医学研究中不可或缺的方法之一。蛋白质荧光标记技术是了解蛋白结构和功能以及药物研发的常用手段,该技术通常是通过特定的化学反应,将荧光染料共价结合在目标蛋白/抗体上,利用荧光染料的荧光特性来提供被研究对象的信息。目前常用来标记蛋白/抗体的荧光染料主要有罗丹明染料、Bodipy染料、香豆素染料以及菁染料等,这些染料经活化后(染料-NHS)可与蛋白/抗体等生物大分子上的自由氨基结合,形成“染料-蛋白/抗体”缀合物,这种标记方式可以很好地保持蛋白/抗体的生物活性。在各种荧光染料中,七甲川花菁染料(Cy7)因具有近红外的吸收/发射波长和高的荧光亮度,是蛋白质荧光标记时最常用的荧光染料之一。然而,该类染料存在弱的光/化学稳定性、易于聚集、缺乏功能化位点等缺点;此外,由于强的疏水性,基于Cy7染料构建的蛋白标记试剂在水中通常以非荧光的H-聚集体存在,使“染料-蛋白/抗体”缀合物的荧光亮度降低,导致检测灵敏度下降,从而直接影响成像效果。因此,发展一种光/化学稳定性强、且水溶性和抗聚集性好的近红外荧光标记试剂将实质性推进其在蛋白荧光标记技术领域中的应用。
发明内容
为解决上述现有技术中存在的技术问题,本发明基于中位2,6-二甲氧基苯基取代的Cy7染料,提供了一种NHS酯功能化的蛋白标记试剂Tag-776-NHS。该试剂不仅合成简单,还解决了基于传统Cy7染料构建的蛋白标记试剂荧光量子收率低、水溶性和光/化学稳定性差、易于聚集的缺点,是一种优良的蛋白标记试剂。本发明使用Tag-776-NHS标记可特异性靶向表皮生长因子的单克隆抗体—帕尼单抗,用于影像A549荷瘤鼠的肿瘤。
本发明的技术方案如下:
一种花菁类近红外荧光标记试剂,其结构式为:
一种如前所述的花菁类近红外荧光标记试剂的制备方法,包括以下步骤:
步骤1,在N2环境下,将PEG-Cl-Cy7、N-羟基丁二酰亚胺和NaH溶于DMF中,搅拌反应,TLC监测反应结束后,混合物经浓缩及柱色谱纯化后得到红色液体PEG-Cy7-Keto;
步骤2,在-78℃、N2环境下,将溶有PEG-Cy7-Keto的无水THF溶液滴加到含有芳基锂试剂1的无水THF溶液中,反应混合物升至室温继续搅拌反应;反应结束后,加入HCl猝灭反应,混合物用CH2Cl2萃取,有机层经干燥、浓缩及柱色谱纯化后得到中间体2;其中,所述芳基锂试剂1的结构式如下:
步骤3,将中间体2和TFA溶于二氯甲烷中,搅拌反应,反应液经浓缩及柱色谱纯化后得到绿色固体Tag-776;
步骤4,将Tag-776、N-羟基琥珀酰亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐溶解于二氯甲烷中,搅拌反应,TLC监测反应结束后,将混合物加入到二氯甲烷中,水洗,有机层经干燥及低温浓缩后得到Tag-776-NHS。
优选地,所述步骤1中PEG-Cl-Cy7、N-羟基丁二酰亚胺、NaH的摩尔比为1:5:5。
优选地,所述步骤1中搅拌反应的温度为室温,时间为12h。
优选地,所述步骤2中PEG-Cy7-Keto和芳基锂试剂1的摩尔比为1:5。
优选地,所述步骤3中搅拌反应的温度为0℃,时间为60min。
优选地,所述步骤4中Tag-776、N-羟基琥珀酰亚胺和1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐的摩尔比为1:4:4。
优选地,所述步骤4中搅拌反应的温度为室温。
一种如前所述的花菁类近红外荧光标记试剂在蛋白荧光标记以及细胞、组织、活体影像中的应用;所述应用为非用于疾病的治疗或诊断方法的应用。
本发明的有益效果如下:
研究表明,在Cy7多甲川共轭链中引入环己烯结构以及中位芳基取代基,能提高染料的荧光量子收率和光/化学稳定性;在中位芳基上引入立体屏蔽基团能进一步提高染料的光稳定性并降低其在水溶液中的聚集。本发明提供的荧光标记试剂Tag-776-NHS结构中包含中位小位阻的2,6-二甲氧基苯基取代基,不仅可以增加其光/化学稳定性,还可以有效阻止Cy7染料在水中的自聚集;此外,该分子结构中还包含两个亲水性的PEG3链,进而使得该分子具有优良的水溶性。因此,Tag-776-NHS是一种优良的蛋白标记试剂,在蛋白标记和肿瘤影像领域具有十分重要的应用价值。
附图说明
图1为化合物PEG-Cy7-Keto的1H NMR图;
图2为化合物PEG-Cy7-Keto的13C NMR图;
图3为化合物PEG-Cy7-Keto的HRMS图;
图4为化合物2的1H NMR图;
图5为化合物2的13C NMR图;
图6为化合物2的HRMS图;
图7为化合物Tag-776的1H NMR图;
图8为化合物Tag-776的13C NMR图;
图9为化合物Tag-776的HRMS图;
图10为化合物Tag-776-NHS的1H NMR图;
图11为化合物Tag-776-NHS的13C NMR图;
图12为化合物Tag-776-NHS的HRMS图;
图13为Tag-776在PBS(10mM,pH=7.4)中随浓度变化(2-40μM)的吸收光谱图;
图14为经PD-10柱和尺寸排阻液相色谱纯化后的Pan-Tag-776的归一化的吸收和激发光谱图(A)和发射光谱图(B);
图15(A)为A549荷瘤小鼠经尾静脉注射Pan-Tag-776(50μg)后不同时间点的活体成像图,收集波长为ICG通道(λex=745nm),(B)为注射Pan-Tag-77648h后离体的肿瘤及重要器官的活体成像图。
具体实施方式
为了进一步阐述本发明的技术方案,下面通过实施例对本发明进行进一步说明。
实施例1荧光标记试剂的制备
一种花菁类近红外荧光标记试剂,其结构式为:
上述花菁类近红外荧光标记试剂的制备方法包括以下步骤:
步骤1,在N2环境下,将PEG-Cl-Cy7(1.50g,1.812mmol)、N-羟基丁二酰亚胺(1.04g,9.058mmol)、NaH(217mg,9.058mmol)溶于DMF中,混合物在室温下搅拌反应,TLC监测反应结束后(约12h),混合物经浓缩及柱色谱(石油醚/乙酸乙酯=1/1(v/v))纯化后得到红色液体PEG-Cy7-Keto(535mg,产率为40.5%)。1H NMR(600MHz,CDCl3)δ8.19(s,2H),7.19(t,J=6.6Hz,4H),6.93(t,J=6.6Hz,2H),6.71(d,J=6.6Hz,2H),5.56(d,J=12.6Hz,2H),3.93(s,4H),3.76(t,J=6Hz,4H),3.66(d,J=6.6Hz,4H),3.63(m,4H),3.61(t,J=5.4Hz,4H),3.52(t,J=4.8Hz,4H),3.37(s,6H),2.62(t,J=5.4Hz,4H),1.88(m,2H),1.68(s,12H);13C NMR(150MHz,CDCl3)δ186.70,162.41,144.31,139.48,132.76,127.96,127.61,121.69,120.64,107.13,92.74,71.92,71.08,70.65,67.24,59.02,46.58,42.85,29.69,28.78,25.87;ESI-MS[M+H]+:calcd for 729.4474,Found729.4471.
步骤2,在-78℃、N2环境下,将溶有PEG-Cy7-Keto(0.2mmol,1eq.)的无水THF溶液缓慢地滴加到含有芳基锂试剂1(5eq.)的无水THF溶液中,反应混合物升至室温继续搅拌反应,反应结束后,加入1N HCl来猝灭反应,混合物用CH2Cl2萃取,有机层经干燥、浓缩及柱色谱(CH2Cl2/CH3OH=30/1-50/1(v/v))纯化后得到中间体2(42mg,产率为31.1%)。1H NMR(600MHz,CD3OD)δ7.51(s,2H),7.35(m,6H),7.26(d,J=7.8Hz,2H),7.19(d,J=7.2Hz,2H),6.30(d,J=13.2Hz,2H),4.30(s,4H),3.87(s,4H),3.81(s,6H),3.59(d,J=2.4Hz,4H),3.55(d,J=2.4Hz,4H),3.50(d,J=3Hz,4H),3.44(d,J=3Hz,4H),3.32(s,6H),2.71(s,4H),2.05(m,2H),1.72(s,9H),1.24(s,12H);13C NMR(150MHz,d-DMSO)δ171.85,164.97,157.26,154.79,144.63,142.98,140.79,133.96,130.30,128.72,124.84,122.69,119.76,111.73,105.01,101.33,81.95,71.66,70.72,70.22,70.14,67.84,58.47,56.64,48.51,44.47,28.33,28.20,27.46,24.55;ESI-MS[M]+:calcd for 949.5573,Found 949.5573.
步骤3,将中间体2(55mg,0.056mmol)和TFA(2.5mL)溶于二氯甲烷中,并在0℃下搅拌反应60min,反应液经浓缩及柱色谱(CH2Cl2/CH3OH=10/1(v/v))纯化后得到绿色固体Tag-776(32mg,产率为61.5%)。1H NMR(600MHz,CD3OD)δ7.59(s,2H),7.35(m,6H),7.25(d,J=7.2Hz,2H),7.17(t,J=6.6Hz,2H),6.30(d,J=13.2Hz,2H),4.28(s,4H),3.86(s,4H),3.81(s,6H),3.59(d,J=2.4Hz,4H),3.54(d,J=3Hz,4H),3.50(d,J=3.6Hz,4H),3.43(s,4H),3.31(s,6H),2.71(s,4H),2.05(m,2H),1.23(s,12H);13C NMR(150MHz,CD3OD)δ172.28,168.21,157.21,155.96,145.44,142.69,140.55,132.98,130.46,128.07,124.29,121.83,119.58,110.68,105.06,100.28,71.49,70.66,70.23,70.07,67.70,57.68,55.38,48.40,44.09,26.68,24.19,20.97;ESI-MS[M]+calcd for 893.4947,Found 893.4951.
步骤4,将Tag-776(20mg,0.0237mmol)、N-羟基琥珀酰亚胺(NHS,11mg,0.0946mmol)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDC,18mg,0.0946mmol)溶解于干燥的二氯甲烷中,混合物在室温下搅拌反应,TLC监测反应结束后,将混合物加入到二氯甲烷中,并用水彻底洗涤以除去过量的EDC、NHS以及EDC的尿素副产物,有机层经干燥及低温浓缩后得到Tag-776-NHS(12mg,产率为54.5%)。1H NMR(600MHz,CD3OD)δ7.67(s,2H),7.37(q,J=7.8Hz,4H),7.28(m,4H),7.18(t,J=7.2Hz,2H),6.31(d,J=13.8Hz,2H),4.29(s,4H),3.86(s,4H),3.85(s,6H),3.59(d,J=3.0Hz,4H),3.54(d,J=2.4Hz,4H),3.49(d,J=3.6Hz,4H),3.43(d,J=2.4Hz,4H),3.00(s,4H),2.71(s,4H),2.05(m,2H),1.25(s,12H),0.89(m,6H);13C NMR(150MHz,d-DMSO)δ171.96,170.88,162.04,157.84,153.60,144.34,142.96,140.83,130.01,128.77,127.02,124.99,122.64,122.56,111.87,105.94,101.50,71.66,70.73,70.23,70.14,67.85,58.76,57.08,48.54,44.51,27.49,26.10,24.50,21.14;ESI-MS[M]+calcd for 990.5111,Found 990.5124.
实施例2荧光标记试剂的性能测试
光物理性质测试:检测Tag-776在CH2Cl2、CH3CN与PBS(10mM,pH=7.4)中的光物理性质。如表1所示,Tag-776的最大吸收/发射值分别位于762-776nm/793-807nm范围,摩尔消光系数值为2.67-3.55×105M-1cm-1,荧光量子产率为0.19-0.36,荧光亮度为51000-128000M-1cm-1,所有这些数值都与中间体2大致相同,说明表明羧基的修饰几乎不会影响染料的光物理性质。
表1化合物2、Tag-776和Pan-Tag-776在二氯甲烷、乙腈和PBS中的光物理性质
选取Cy7(Φ=0.24in MeOH)作为参比;bPBS(10mM,pH 7.4,包含30% CH3CN以确保所有染料溶解);bPBS(10mM,pH 7.4)。
水溶性和自聚集测试:评估Tag-776在PBS(10mM,pH 7.4)中的溶解性和自聚集情况。如图13所示,由于Tag-776分子结构中存在两条亲水性的(PEG)3链以及抗聚集的中位2,6-二甲氧基苯基取代基,因此该染料不仅具有优良的水溶性(羧基负离子形式的Lop=-0.29),重要的是,即使当其浓度达到40μM时,在PBS中也没有观察到任何聚集峰。
鉴于此,基于Tag-776制备N-羟基琥珀酰亚胺活性酯Tag-776-NHS,用来标记单克隆抗体(mAb)。
实施例3荧光标记试剂的应用
表皮生长因子受体(EGFR)是一个巨大的跨膜糖蛋白,包括HER1-HER4,在多种癌细胞的膜表面过量表达,因此,采用荧光标记试剂Tag-776-NHS特异性靶向表皮生长因子受体(EGFR)的mAb帕尼单抗(Panitumumab)以实现影像癌细胞。使用标准的蛋白标记方法,Tag-776-NHS可以在pH=8.5的PBS中与帕尼单抗(Panitumumab)结合,并经PD-10柱和尺寸排阻柱先后纯化后,得到“染料-抗体”肿瘤靶向试剂Pan-Tag-776(在PBS中,λabs/λabs=768/800nm)。经计算,当Tag-776-NHS与帕尼单抗反应的摩尔比为10:1时,标记度(DOL)为3(图14)。
随后,将Pan-Tag-776(50μg)经尾静脉注射到A549荷瘤鼠体内,并在注射后6、24、32和48h进行成像。如图15A所示,A549荷瘤鼠肿瘤部位处的荧光信号在注射24h后明显增强,并在32h时达到最大值,肿瘤与正常组织的荧光信号比率(T/N)高达3.2,高于临床可接受的阈值2.0;注射48h后,肿瘤部位的荧光几乎观察不到。最后,肿瘤及主要器官,包括心、肝、脾、肺和肾,被切除并成像。如图15B所示,肝脏和肾脏中残留的荧光表明Pan-Tag-776经历了肾脏与肝脏代谢。上述结果表明,Pan-Tag-776可以高对比度影像肿瘤,因此是一个潜在的肿瘤影像工具。
综上所述,本发明采用“菁酮法”,基于中位立体位阻芳基取代的Cy7荧光染料构建了一个NHS酯功能化的蛋白标记试剂Tag-776-NHS。实验结果显示,Tag-776-NHS不仅具有强的水溶性,而且有效抑制了染料在水中的自聚集,解决了基于经典Cy7染料构建的蛋白标记试剂水溶性和光/化学稳定性差、易于聚集等缺点。利用Tag-776-NHS荧光标记试剂可特异性靶向EGFR的mAb—帕尼单抗,从而用于高对比度影像肿瘤,能够在蛋白标记、肿瘤成像等领域得到广泛应用。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种花菁类近红外荧光标记试剂,其特征在于,其结构式为:
2.一种权利要求1所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,包括以下步骤:
步骤1,在N2环境下,将PEG-Cl-Cy7、N-羟基丁二酰亚胺和NaH溶于DMF中,搅拌反应,TLC监测反应结束后,混合物经浓缩及柱色谱纯化后得到红色液体PEG-Cy7-Keto;
步骤2,在-78℃、N2环境下,将溶有PEG-Cy7-Keto的无水THF溶液滴加到含有芳基锂试剂1的无水THF溶液中,反应混合物升至室温继续搅拌反应;反应结束后,加入HCl猝灭反应,混合物用CH2Cl2萃取,有机层经干燥、浓缩及柱色谱纯化后得到中间体2;其中,所述芳基锂试剂1的结构式如下:
步骤3,将中间体2和TFA溶于二氯甲烷中,搅拌反应,反应液经浓缩及柱色谱纯化后得到绿色固体Tag-776;
步骤4,将Tag-776、N-羟基琥珀酰亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐溶解于二氯甲烷中,搅拌反应,TLC监测反应结束后,将混合物加入到二氯甲烷中,水洗,有机层经干燥及低温浓缩后得到Tag-776-NHS。
3.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤1中PEG-Cl-Cy7、N-羟基丁二酰亚胺、NaH的摩尔比为1:5:5。
4.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤1中搅拌反应的温度为室温,时间为12h。
5.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤2中PEG-Cy7-Keto和芳基锂试剂1的摩尔比为1:5。
6.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤3中搅拌反应的温度为0℃,时间为60min。
7.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤4中Tag-776、N-羟基琥珀酰亚胺和1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐的摩尔比为1:4:4。
8.根据权利要求2所述的花菁类近红外荧光标记试剂的制备方法,其特征在于,所述步骤4中搅拌反应的温度为室温。
9.一种权利要求1所述的花菁类近红外荧光标记试剂在蛋白荧光标记以及细胞、组织、活体影像中的应用;所述应用为非用于疾病的治疗或诊断方法的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410168756.0A CN118047766A (zh) | 2024-02-06 | 2024-02-06 | 一种花菁类近红外荧光标记试剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410168756.0A CN118047766A (zh) | 2024-02-06 | 2024-02-06 | 一种花菁类近红外荧光标记试剂及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118047766A true CN118047766A (zh) | 2024-05-17 |
Family
ID=91044238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410168756.0A Pending CN118047766A (zh) | 2024-02-06 | 2024-02-06 | 一种花菁类近红外荧光标记试剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118047766A (zh) |
-
2024
- 2024-02-06 CN CN202410168756.0A patent/CN118047766A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109336909B (zh) | 具有聚集诱导发光性质的近红外二区荧光化合物及制备方法、纳米粒胶束及其应用 | |
US6258340B1 (en) | In-vivo diagnostic method by near infrared radiation | |
CN109180680B (zh) | 一种紫外光触发交联型近红外分子探针及其制备方法与应用 | |
ES2670852T3 (es) | Colorantes con policiclo y uso de los mismos | |
EP4015518B1 (en) | Active-targeting near-infrared fluorescent molecule for targeting folate receptor and preparation method therefor | |
CN110684017B (zh) | 高稳定性近红外二区小分子荧光探针及其制备方法和应用 | |
EA009386B1 (ru) | Гидрофильные, реакционные в отношении тиол-группы цианиновые красители, и их конъюгаты с биомолекулами для флюоресцентной диагностики | |
EP1281405B1 (de) | Kurzkettige Peptid-Farbstoffkonjugate als Kontrastmittel für die optische Diagnostik | |
CN114790215B (zh) | 基于喹喔啉的d-a-d近红外二区荧光分子及其制备方法和应用 | |
WO2007088129A2 (en) | Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging | |
CN113956265B (zh) | 一种基于丙二醛响应的近红外分子探针、制备方法及其应用 | |
EP0946203B1 (en) | Tricyclic functional dyes for contrast enhancement in optical imaging | |
CN116813704B (zh) | 一种肿瘤靶向荧光分子探针及其应用 | |
CN107629016B (zh) | 伊文氏蓝配合物及其制备方法和应用 | |
CN105111773B (zh) | 一类氨基菁类荧光染料及其制备方法和应用 | |
CN108066777A (zh) | 肿瘤靶向核磁共振-荧光超分子成像造影剂及制备和应用 | |
ES2202622T3 (es) | Colorantes con funcionalidad delta 1,2 biciclo 4,4,0) para mejorar el contraste en la formacion de imagenes opticas. | |
CN118047766A (zh) | 一种花菁类近红外荧光标记试剂及其制备方法和应用 | |
US5723104A (en) | Monocyclic functional dyes for contrast enhancement in optical imaging | |
CN107522773B (zh) | 一种五肽改性罗丹明b化合物及其制备方法和应用 | |
CN110201189A (zh) | 白蛋白结合型近红外荧光染料-马来酰亚胺共轭物 | |
CN113563298A (zh) | 一类含水溶性取代基罗丹明荧光染料其制备方法和应用 | |
JP2021520424A (ja) | アザシアニン色素及びその使用 | |
CN115337409B (zh) | 白蛋白结合型近红外荧光探针-脂肪酸共轭物及其制备方法和应用 | |
CN111892598B (zh) | 含有苝酰亚胺结构的咪唑类磁性离子液体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |